Trust Co of Kansas Has $7.39 Million Position in Merck & Co., Inc. $MRK

Trust Co of Kansas decreased its stake in Merck & Co., Inc. (NYSE:MRK) by 10.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 70,164 shares of the company’s stock after selling 8,414 shares during the period. Merck & Co., Inc. comprises about 3.4% of Trust Co of Kansas’ holdings, making the stock its 10th biggest position. Trust Co of Kansas’ holdings in Merck & Co., Inc. were worth $7,385,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $25,000. High Note Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the period. Tucker Asset Management LLC bought a new position in Merck & Co., Inc. during the 4th quarter valued at about $34,000. Entrust Financial LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $37,000. Finally, United Financial Planning Group LLC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $31,000. Institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on MRK shares. Wells Fargo & Company reduced their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Barclays started coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $128.18.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reached a settlement of more than $50 million to resolve over 200 Gardasil-related lawsuits, removing a significant legal overhang and helping investors refocus on the company’s core business and pipeline. Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
• Positive Sentiment: Merck recently broke above both its 20-day and 50-day moving averages, a technical signal that traders often view as a sign of improving short-term momentum. Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
• Positive Sentiment: Merck’s oncology franchise continues to draw attention after ASCO 2026 updates highlighted Keytruda’s strength in solid tumors and other pipeline assets aimed at offsetting future exclusivity pressure. ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
• Positive Sentiment: Merck’s collaboration with Moderna on a personalized mRNA cancer vaccine also got a boost from positive long-term data disclosed by Moderna, reinforcing investor interest in the partnership. Why Is Moderna (MRNA) Stock Rocketing Higher Today
• Neutral Sentiment: Merck’s conference appearance and oncology strategy update likely kept investor focus on the pipeline, but the items available do not indicate a major new catalyst beyond ongoing progress. Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification – Slideshow

Merck & Co., Inc. Price Performance

MRK opened at $121.05 on Monday. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The business’s fifty day simple moving average is $116.55 and its 200-day simple moving average is $112.52. The company has a market capitalization of $298.96 billion, a price-to-earnings ratio of 34.10, a PEG ratio of 2.72 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the firm posted $2.22 earnings per share. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.